The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) membrane (M) protein inhibits type I and III interferon production by targeting RIG-I/MDA-5 signaling
Open accessPublished version of a preprint
Abstract
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has quickly spread worldwide and has affected more than 10 million individuals. A typical feature of COVID-19 is the suppression of type I and III interferon (IFN)-mediated antiviral immunity. However, the molecular mechanism by which SARS-CoV-2 evades antiviral immunity remains elusive. Here, we reported that the SARS-CoV-2 membrane (M) protein inhibits the production of type I and III IFNs induced by the cytosolic dsRNA-sensing pathway mediated by RIG-I/MDA-5-MAVS signaling. In addition, the SARS-CoV-2 M protein suppresses type I and III IFN induction stimulated by SeV infection or poly (I:C) transfection. Mechanistically, the SARS-CoV-2 M protein interacts with RIG-I, MAVS, and TBK1, thus preventing the formation of the multiprotein complex containing RIG-I, MAVS, TRAF3, and TBK1 and subsequently impeding the phosphorylation, nuclear translocation, and activation of IRF3. Consequently, ectopic expression of the SARS-CoV-2 M protein facilitates the replication of vesicular stomatitis virus. Taken together, these results indicate that the SARS-CoV-2 M protein antagonizes type I and III IFN production by targeting RIG-I/MDA-5 signaling, which subsequently attenuates antiviral immunity and enhances viral replication. This study provides insight into the interpretation of SARS-CoV-2-induced antiviral immune suppression and illuminates the pathogenic mechanism of COVID-19.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As is typical for many viruses, IFNs inhibit viral replication and are elevated during COVID-19, which helps drive Th1 and Th17 responses. 149,150”
From COVID-19, Myocarditis and Pericarditis (2023) · cites this paper as [149]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
A new coronavirus associated with human respiratory disease in China
Wu, F., Zhao, S., Yu, B., Chen, Y.-M., Wang, W., Song, Z.-G., Hu, Y., Tao, Z.-W., Tian, J.-H., Pei, Y.-Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2008-3 · Cited by 11,688
Origin and evolution of pathogenic coronaviruses
Cui, J., Li, F., & Shi, Z. (2018) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0118-9 · Cited by 5,729
Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway
Sun, L., Wu, J., Du, F., Chen, X., & Chen, Z. J. (2013) · Science · doi:10.1126/science.1232458 · Cited by 4,996
Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19
Blanco-Melo, D., Nilsson-Payant, B. E., Liu, W.-C., Uhl, S., Hoagland, D., Møller, R., Jordan, T. X., Oishi, K., Panis, M., Sachs, D., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.026 · Cited by 4,222
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
Hadjadj, J., Yatim, N., Barnabei, L., Corneau, A., Boussier, J., Smith, N., Péré, H., Charbit, B., Bondet, V., Chenevier-Gobeaux, C., et al. (2020) · Science · doi:10.1126/science.abc6027 · Cited by 2,984
Ziegler, C. G. K., Allon, S. J., Nyquist, S. K., Mbano, I. M., Miao, V. N., Tzouanas, C. N., Cao, Y., Yousif, A. S., Bals, J., Hauser, B. M., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.035 · Cited by 2,284
The Architecture of SARS-CoV-2 Transcriptome
Kim, D., Lee, J.-Y., Yang, J.-S., Kim, J. W., Kim, V. N., & Chang, H. (2020) · Cell · doi:10.1016/j.cell.2020.04.011 · Cited by 2,123
Longitudinal analyses reveal immunological misfiring in severe COVID-19
Lucas, C., Wong, P., Klein, J., Castro, T. B. R., Silva, J., Sundaram, M., Ellingson, M. K., Mao, T., Oh, J. E., Israelow, B., et al. (2020) · Nature · doi:10.1038/s41586-020-2588-y · Cited by 2,074
Cited by
Sorted by citations
Regulation of RIG-I-like receptor-mediated signaling: interaction between host and viral factors
Onomoto, K., Onoguchi, K., & Yoneyama, M. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00602-7 · Cited by 440
Bai, Z., Cao, Y., Liu, W.-J., & Li, J. (2021) · Viruses · doi:10.3390/v13061115 · Cited by 320
Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic
To, K. K., Sridhar, S., Chiu, K. H., Hung, D. L. L., Li, X., Hung, I. F., Tam, A. R., Chung, T. W., Chan, J. F., Zhang, J., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1898291 · Cited by 359
Self-citationInnate immune and inflammatory responses to SARS-CoV-2: Implications for COVID-19
Lowery, S. A., Sariol, A., & Perlman, S. M. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.05.004 · Cited by 303
SARS-CoV-2-Specific Immune Response and the Pathogenesis of COVID-19
Gusev, E., Sarapultsev, A., Владимировна, С. Л., & Черешнев, В. А. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031716 · Cited by 326
Han, L., Zhuang, M., Deng, J., Zheng, Y., Zhang, J., Nan, M., Zhang, X., Gao, C., & Wang, P. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27050 · Cited by 259
Self-citationInnate immune sensing of coronavirus and viral evasion strategies
Kasuga, Y., Zhu, B., Jang, K., & Yoo, J. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00602-1 · Cited by 236
Wu, W., Cheng, Y., Zhou, H. W., Sun, C., & Zhang, S. (2023) · Virology Journal · doi:10.1186/s12985-023-01968-6 · Cited by 234
Li, F., Li, J., Wang, P., Yang, N., Huang, J., Ou, J., Xu, T., Zhao, X., Liu, T., Huang, X., et al. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166260 · Cited by 211
Self-citationCOVID-19, Myocarditis and Pericarditis
Fairweather, D., Beetler, D. J., Di Florio, D. N., Musigk, N., Heidecker, B., & Cooper, L. T. (2023) · Circulation Research · doi:10.1161/circresaha.123.321878 · Cited by 194
Zheng, Y., Deng, J., Han, L., Zhuang, M., Xu, Y., Zhang, J., Nan, M., Xiao, Y., Zhan, P., Liu, X., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00878-3 · Cited by 175
Self-citationSui, L., Zhao, Y., Wang, W., Wu, P., Wang, Z., Yu, Y., Hou, Z., Tan, G., & Liu, Q. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.662989 · Cited by 160
Covid-19: Perspectives on Innate Immune Evasion
Taefehshokr, N., Taefehshokr, S., Hemmat, N., & Heit, B. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.580641 · Cited by 152
Wu, Y., Ma, L., Cai, S., Zhuang, Z., Zhao, Z., Jin, S., Xie, W., Zhou, L., Zhang, L., Zhao, J., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00575-7 · Cited by 151
Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?
Milne, G., Hames, T., Scotton, C. J., Gent, N., Johnsen, A., Anderson, R. M., & Ward, T. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00407-0 · Cited by 123
Sensing of cytoplasmic chromatin by cGAS activates innate immune response in SARS-CoV-2 infection
Zhou, Z. L., Zhang, X., Lei, X., Xiao, X., Jiao, T., Ma, R., Dong, X., Jiang, Q., Wang, W., Shi, Y., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00800-3 · Cited by 120
Regulation of antiviral innate immune signaling and viral evasion following viral genome sensing
Chathuranga, K., Weerawardhana, A., Dodantenna, N., & Lee, J. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00691-y · Cited by 110
SARS‐CoV‐2 ORF10 antagonizes STING‐dependent interferon activation and autophagy
Han, L., Zheng, Y., Deng, J., Nan, M., Xiao, Y., Zhuang, M., Zhang, J., Wang, W. J., Gao, C., & Wang, P. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27965 · Cited by 109
Self-citationDependence of SARS-CoV-2 infection on cholesterol-rich lipid raft and endosomal acidification
Li, X., Zhu, W., Fan, M., Zhang, J., Peng, Y., Huang, F., Wang, N., He, L., Zhang, L., Holmdahl, R., et al. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.04.001 · Cited by 109
Self-citationCOVID19 Disease Map, a computational knowledge repository of virus–host interaction mechanisms
Ostaszewski, M., Niarakis, A., Mazein, A., Kuperstein, I., Phair, R. D., Resendiz, A. O., Singh, V., Aghamiri, S. S., Acencio, M. L., Glaab, E., et al. (2021) · Molecular Systems Biology · doi:10.15252/msb.202110387 · Cited by 104
The crucial regulatory role of type I interferon in inflammatory diseases
Ji, L., Li, T., Chen, H., Yang, Y., Liu, J., Liu, J., Qiao, W., & Chen, H. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01188-z · Cited by 107
Mechanisms of Antiviral Immune Evasion of SARS-CoV-2
Beyer, D. K., & Forero, A. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.167265 · Cited by 96
Sui, C., Xiao, T., Zhang, S., Zeng, H., Zheng, Y., Liu, B., Xu, G., Gao, C., & Zhang, Z. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2100684 · Cited by 93
Self-citationPhase separation by the SARS-CoV-2 nucleocapsid protein: Consensus and open questions
Cascarina, S. M., & Ross, E. D. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101677 · Cited by 91
McCarron, S., Bathon, B., Conlon, D. M., Abbey, D., Rader, D. J., Gawronski, K., Brown, C. D., Olthoff, K. M., Shaked, A., & Raabe, T. D. (2021) · Hepatology · doi:10.1002/hep.31857 · Cited by 89
COVID-19 virtual patient cohort suggests immune mechanisms driving disease outcomes
Jenner, A. L., Aogo, R. A., Alfonso, S., Crowe, V., Deng, X., Smith, A. P., Morel, P. A., Davis, C. L., Smith, A. M., & Craig, M. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009753 · Cited by 91
SARS-CoV-2 membrane protein causes the mitochondrial apoptosis and pulmonary edema via targeting BOK
Yang, Y., Wu, Y., Meng, X., Wang, Z., Younis, M., Liu, Y., Wang, P., & Huang, X. (2022) · Cell Death & Differentiation · doi:10.1038/s41418-022-00928-x · Cited by 88
Self-citationLiu-Wei, W., Kafkas, Ş., Chen, J., Dimonaco, N. J., Tegner, J. N., & Hoehndorf, R. (2021) · Bioinformatics · doi:10.1093/bioinformatics/btab147 · Cited by 74
The battle between host and SARS-CoV-2: Innate immunity and viral evasion strategies
Zhang, S., Wang, L., & Cheng, G. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.02.014 · Cited by 78
Fung, S., Siu, K., Lin, H., Yeung, M. L., & Jin, D. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59943 · Cited by 79
Innate Immune Sensing of Viruses and Its Consequences for the Central Nervous System
Singh, H., Koury, J., & Kaul, M. (2021) · Viruses · doi:10.3390/v13020170 · Cited by 75
SARS-CoV-2 Nsp5 Activates NF-κB Pathway by Upregulating SUMOylation of MAVS
Li, W., Qiao, J., You, Q., Zong, S., Peng, Q., Liu, Y., Hu, S., Liu, W., Li, S., Shu, X., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.750969 · Cited by 72
SARS-CoV-2 mutations: the biological trackway towards viral fitness
Majumdar, P., & Niyogi, S. (2021) · Epidemiology and Infection · doi:10.1017/s0950268821001060 · Cited by 70
Molecular evolution of SARS‐CoV‐2 from December 2019 to August 2022
Wolf, J. M., Wolf, L. M., Bello, G. L., Maccari, J. G., & Nasi, L. A. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28366 · Cited by 69
The MAVS Immune Recognition Pathway in Viral Infection and Sepsis
Sharma, A., Kontodimas, K., & Bosmann, M. (2021) · Antioxidants and Redox Signaling · doi:10.1089/ars.2021.0167 · Cited by 65
Pathologic Mechanisms of the Newcastle Disease Virus
Zhang, D., Ding, Z., & Xu, X. (2023) · Viruses · doi:10.3390/v15040864 · Cited by 64
Bhowal, C., Ghosh, S., Ghatak, D., & De, R. (2022) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-022-04593-z · Cited by 63
Immune evasion of SARS-CoV-2 from interferon antiviral system
Min, Y., Huang, M., Sun, X., Dèng, F., Wáng, H., & Ning, Y. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.07.023 · Cited by 65
Xu, S., Jin, T., & Weng, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.951614 · Cited by 61
Innate immune responses in pneumonia
Korkmaz, F. T., & Traber, K. E. (2023) · Pneumonia · doi:10.1186/s41479-023-00106-8 · Cited by 73
The ins and outs of SARS-CoV-2 variants of concern (VOCs)
Salehi-Vaziri, ., Fazlalipour, M., Khorrami, S. M. S., Azadmanesh, K., Pouriayevali, M. H., Jalali, T., Shoja, Z., & Maleki, A. (2022) · Archives of Virology · doi:10.1007/s00705-022-05365-2 · Cited by 61
Understanding COVID-19 in children: immune determinants and post-infection conditions
Rotulo, G. A., & Palma, P. (2023) · Pediatric Research · doi:10.1038/s41390-023-02549-7 · Cited by 60
COVID-19 and pregnancy: clinical outcomes; mechanisms, and vaccine efficacy
Kumar, D., Verma, S., & Mysorekar, I. U. (2022) · Translational research · doi:10.1016/j.trsl.2022.08.007 · Cited by 59
Shen, L., Bard, J. D., Triche, T. J., Judkins, A. R., Biegel, J. A., & Gai, X. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1922097 · Cited by 54
Ubiquitination of SARS-CoV-2 NSP6 and ORF7a Facilitates NF-κB Activation
Nishitsuji, H., Iwahori, S., Ohmori, M., Shimotohno, K., & Murata, T. (2022) · mBio · doi:10.1128/mbio.00971-22 · Cited by 56
Therapeutic strategy targeting host lipolysis limits infection by SARS-CoV-2 and influenza A virus
Baek, Y., Kwon, H., Sharif, M., Lim, J., Lee, I., Ryu, Y. B., Lee, J.-I., Kim, J., Lee, Y.-S., Kim, D., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01223-4 · Cited by 53
Circulating Type I Interferon Levels and COVID-19 Severity: A Systematic Review and Meta-Analysis
da Silva, R. P., Gonçalves, J. I. B., Zanin, R. F., Schuch, F. B., & de Souza, A. P. D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.657363 · Cited by 50
MAVS: A Two-Sided CARD Mediating Antiviral Innate Immune Signaling and Regulating Immune Homeostasis
Chen, Y., Shi, Y., Wu, J., & Qi, N. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.744348 · Cited by 52
Characterization of SARS-CoV-2 Evasion: Interferon Pathway and Therapeutic Options
Znaidia, M., Demeret, C., van der Werf, S., & Komarova, A. V. (2022) · Viruses · doi:10.3390/v14061247 · Cited by 57
Zhang, Y., Shang, L., Zhang, J., Liu, Y., Jin, C., Zhao, Y., Lei, X., Wang, W., Xiao, X., Zhang, X., et al. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.10.008 · Cited by 50
Self-citationAndi, B., Kumaran, D., Kreitler, D. F., Soares, A. S., Keereetaweep, J., Jakoncic, J., Lazo, E., Shi, W., Fuchs, M. R., Sweet, R. M., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-15930-z · Cited by 51
Barh, D., Tiwari, S., Rodrigues Gomes, L. G., Ramalho Pinto, C. H., Andrade, B. S., Ahmad, S., Aljabali, A. A. A., Alzahrani, K. J., Banjer, H. J., Hassan, S. S., et al. (2023) · Inflammation · doi:10.1007/s10753-022-01734-w · Cited by 50
Zhang, Q., Chen, Z., Huang, C., Sun, J., Xue, M., Feng, T., Pan, W., Wang, K., & Dai, J. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.766922 · Cited by 55
The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection
Moga, E., Lynton‐Pons, E., & Domingo, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.904686 · Cited by 48
TREM-2 is a sensor and activator of T cell response in SARS-CoV-2 infection
Wu, Y., Wang, M., Yin, H., Ming, S., Li, X., Jiang, G., Liu, Y., Wang, P., Zhou, G., Liu, L., et al. (2021) · Science Advances · doi:10.1126/sciadv.abi6802 · Cited by 45
Self-citationEmergence of SARS-CoV-2 Variants in the World: How Could This Happen?
Parra-Lucares, A., Segura, P., Rojas, V. A., Pumarino, C., Saint-Pierre, G., & Toro, L. (2022) · Life · doi:10.3390/life12020194 · Cited by 49
Xu, J.-B., Guan, W., Zhang, Y., Qiu, Z.-E., Chen, L., Hou, X.-C., Yue, J., Zhou, Y.-Y., Sheng, J., Zhao, L., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01753-z · Cited by 44
Immunotoxic role of organophosphates: An unseen risk escalating SARS-CoV-2 pathogenicity
Rajak, P., Ganguly, A., Sarkar, S., Mandi, M., Dutta, M., Podder, S., Khatun, S., & Roy, S. (2021) · Food and Chemical Toxicology · doi:10.1016/j.fct.2021.112007 · Cited by 46
Glanz, A., Chakravarty, S., Varghese, M., Kottapalli, A., Fan, S., Chakravarti, R., & Chattopadhyay, S. (2021) · Viruses · doi:10.3390/v13040575 · Cited by 43
Seviiri, M., Law, M. H., Ong, J., Gharahkhani, P., Fontanillas, P., Aslibekyan, S. W., Auton, A., Babalola, E., Bell, R. K., Bielenberg, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35345-8 · Cited by 44
Interferon at the crossroads of SARS-CoV-2 infection and COVID-19 disease
Samuel, C. E. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.104960 · Cited by 50
Zhang, X., Yang, Z., Pan, T. S., Sun, Q., Chen, Q., Wang, P., Li, X., & Kuang, E. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011792 · Cited by 37
Self-citationDeng, J., Zheng, Y., Zheng, S., Nan, M., Han, L., Zhang, J., Jin, Y., Pan, J., Gao, C., & Wang, P. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28561 · Cited by 40
Self-citationVirus Caused Imbalance of Type I IFN Responses and Inflammation in COVID-19
Zhang, J., Zhao, C., & Zhao, W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.633769 · Cited by 36
Self-citationGilbert, C., Lefeuvre, C., Preisser, L., Pivert, A., Soleti, R., Blanchard, S., Delneste, Y., Ducancelle, A., Couez, D., & Jeannin, P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.750279 · Cited by 40
Beucher, G., Blondot, M.-L., Celle, A., Pied, N., Recordon-Pinson, P., Estèves, P., Faure, M., Métifiot, M., Lacomme, S., Dacheux, D., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2202370119 · Cited by 38
Induction of Innate Immune Response by TLR3 Agonist Protects Mice against SARS-CoV-2 Infection
Tamir, H., Melamed, S., Noam Erez, A., Politi, B., Yahalom-Ronen, Y., Achdout, H., Lazar, S., Gutman, H., Avraham, R., Weiss, S., et al. (2022) · Viruses · doi:10.3390/v14020189 · Cited by 37
Innate Immune Response in SARS-CoV-2 Infection
Schiuma, G., Beltrami, S., Bortolotti, D., Rizzo, S., & Rizzo, R. (2022) · Microorganisms · doi:10.3390/microorganisms10030501 · Cited by 39
Tonutti, A., Motta, F., Ceribelli, A., Isailovic, N., Selmi, C. F., & Santis, M. D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.937667 · Cited by 36
Autoimmunity and Immunodeficiency in Severe SARS-CoV-2 Infection and Prolonged COVID-19
Garmendia, J. V., García, A. H., Sanctis, C. V. D., Hajdúch, M., & Sanctis, J. B. D. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb45010003 · Cited by 34
Immune correlates of protection for SARS-CoV-2, Ebola and Nipah virus infection
Escudero-Pérez, B., Lawrence, P., & Castillo‐Olivares, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1156758 · Cited by 37
Chen, N., Jin, J., Zhang, B., Meng, Q., Lu, Y., Liang, B., Deng, L., Qiao, B., & Zheng, L. (2024) · Emerging Microbes & Infections · doi:10.1080/22221751.2024.2341144 · Cited by 33
Alterations in the Composition of Intestinal DNA Virome in Patients With COVID-19
Lü, Z., Zhou, H., Wu, W., Fu, T., Yan, M., He, Z., Sun, S., Ji, Z., & Shao, Z. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.790422 · Cited by 30
Zhang, X., Han, L., Hou, J., Yang, H., Xu, H., Li, G., Shu, Q., Zhu, D., Zheng, Y., & Gao, C. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114248 · Cited by 35
Self-citationPham, M. T., Yang, A. J., Kao, M., Gankhuyag, U., Zayabaatar, E., Jin, S.-L. C., & Huang, C.-M. (2021) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2021.108821 · Cited by 32
Strategies for fighting pandemic virus infections: Integration of virology and drug delivery
Nakamura, T., Isoda, N., Sakoda, Y., & Harashima, H. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.046 · Cited by 32
Zhang, J.-S., Yuan, S., Peng, Q., Ding, Z., Hao, W., Peng, G., Xiao, S., & Fang, L. (2022) · Journal of Virology · doi:10.1128/jvi.00400-22 · Cited by 31
Self-citationVanderwall, E. R., Barrow, K. A., Rich, L. M., Read, D. F., Trapnell, C., Okoloko, O., Ziegler, S. F., Hallstrand, T. S., White, M. P., & Debley, J. S. (2022) · Scientific Reports · doi:10.1038/s41598-022-10763-2 · Cited by 31
Xie, S., Xie, X., Zhao, X. Y., Liu, F., Wang, Y., Ping, J., & Ji, Z. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbad261 · Cited by 32
Yan, T., Xiao, R., Wang, N., Shang, R., & Lin, G. (2021) · Theranostics · doi:10.7150/thno.59293 · Cited by 32
Jahangirian, E., Jamal, G. A., Nouroozi, M., & Mohammadpour, A. (2021) · Immunogenetics · doi:10.1007/s00251-021-01228-3 · Cited by 29
McGill, A. R., Khalil, R., Dutta, R., Green, R. J., Howell, M., Mohapatra, S., & Mohapatra, S. S. (2021) · Infectious Disease Reports · doi:10.3390/idr13010013 · Cited by 30
SARS-CoV-2 NSP12 Protein Is Not an Interferon-β Antagonist
Li, A., Zhao, K., Zhang, B., Hua, R.-H., Fang, Y., Jiang, W., Zhang, J., Hui, L., Zheng, Y., Li, Y., et al. (2021) · Journal of Virology · doi:10.1128/jvi.00747-21 · Cited by 30
Self-citationTranscriptomic profiling of cardiac tissues from SARS‐CoV ‐2 patients identifies DNA damage
Kulasinghe, A., Liu, N., Tan, C. W., Monkman, J. H., Sinclair, J. E., Bhuva, D. D., Godbolt, D., Pan, L., Nam, A., Sadeghirad, H., et al. (2022) · Immunology · doi:10.1111/imm.13577 · Cited by 30
Coronavirus infection: An immunologists' perspective
Sanctis, J. B. D., García, A. H., Moreno, D., & Hajdúch, M. (2021) · Scandinavian Journal of Immunology · doi:10.1111/sji.13043 · Cited by 27
Profiling of SARS-CoV-2 Subgenomic RNAs in Clinical Specimens
Chen, Z., Ng, R. W. Y., Lui, G. C.-Y., Ling, L., Chow, C., Yeung, A. C. M., Boon, S. S., Wang, M. H., Chan, K. C. C., Chan, R. W. Y., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.00182-22 · Cited by 28
The SARS-CoV-2 protein ORF3c is a mitochondrial modulator of innate immunity
Stewart, H., Lu, Y., O’Keefe, S. M., Valpadashi, A., Cruz‐Zaragoza, L. D., Michel, H. A., Nguyen, S. K., Carnell, G., Lukhovitskaya, N. I., Milligan, R., et al. (2023) · iScience · doi:10.1016/j.isci.2023.108080 · Cited by 28
Liu, T., Feng, M., Wen, Z., He, Y., Lin, W., & Zhang, M. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s329697 · Cited by 29
Zhu, Y., Zhang, Z., Song, J. T., Qian, W., Xiangqian, G., Yang, C. J., Shen, N., Xue, F., & Tang, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.767726 · Cited by 27
Wang, M., Zhao, Y., Liu, J., & Li, T. (2022) · MedComm – Future Medicine · doi:10.1002/mef2.29 · Cited by 27
ACE2 and Innate Immunity in the Regulation of SARS-CoV-2-Induced Acute Lung Injury: A Review
Qu, L., Chen, C., Yin, T., Fang, Q., Hong, Z.-Z., Zhou, R., Tang, H., & Dong, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111483 · Cited by 23
Deng, J., Zheng, S., Xiao, Y., Nan, M., Zhang, J., Han, L., Zheng, Y., Yu, Y., Ding, Q., Gao, C., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28680 · Cited by 24
Self-citationInflammasomes: a rising star on the horizon of COVID-19 pathophysiology
Wang, M., Yu, F., Chang, W., Zhang, Y., Zhang, L., & Li, P. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1185233 · Cited by 25
Acute COVID-19 and LongCOVID syndrome – molecular implications for therapeutic strategies - review
Michalak, K. P., Michalak, A. Z., & Brenk-Krakowska, A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1582783 · Cited by 27
Batool, M., Kim, M. S., & Choi, S. (2021) · Medicinal Research Reviews · doi:10.1002/med.21845 · Cited by 23
COVID-19 pandemic: the delta variant, T-cell responses, and the efficacy of developing vaccines
Biswas, B. K., Chattopadhyay, S., Hazra, S., Hansda, A. K., & Goswami, R. (2022) · Inflammation Research · doi:10.1007/s00011-022-01555-5 · Cited by 25
Alterations in gut immunological barrier in SARS-CoV-2 infection and their prognostic potential
Eleftheriotis, G., Tsounis, E. P., Aggeletopoulou, I., Dousdampanis, P., Triantos, C. K., Mouzaki, Α., Marangos, M. N., & Assimakopoulos, S. F. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1129190 · Cited by 22
SARS-CoV-2 and the DNA damage response
Grand, R. J. A. (2023) · Journal of General Virology · doi:10.1099/jgv.0.001918 · Cited by 25
Molecular detection of SARS-CoV-2 being challenged by virus variation and asymptomatic infection
Jiang, C., Li, X., Ge, C., Ding, Y., Zhang, T., Cao, S., Meng, L., & Lu, S. (2021) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2021.03.006 · Cited by 21
Grossegesse, M., Bourquain, D. R., Neumann, M., Schaade, L., Schulze, J., Mache, C., Wolff, T., Nitsche, A., & Doellinger, J. (2022) · Journal of Proteome Research · doi:10.1021/acs.jproteome.1c00783 · Cited by 21
Metadata
- Authors
- Zheng, Y., Zhuang, M.-W., Han, L., Zhang, J., Nan, M.-L., Zhan, P., Kang, D., Liu, X., Gao, C., & Wang, P.-H.
- Affiliations
- Shandong University (CN)
- Corresponding author
- Gao, Chengjiang
- Wang, Pei-Hui
- ORCID
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2020-12-28
- Volume
- 5
- Issue
- 1
- Pages
- 299-299
- ISSN
- 2059-3635 (ISSN-L)
- PMC
- PMC7768267
- OpenAlex
- W3115832826
- Cited by
- 302
- References
- 47
- Citations by year
- 2026: 13 · 2025: 23 · 2024: 36 · 2023: 56 · 2022: 93 · 2021: 80 · 2020: 1
- FWCI
- 20.14
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Funders
- Shandong University (2020XGB03)
- National Natural Science Foundation of China (81525012, 81930039, 31730026, 81901604, COVID-19)
- China Postdoctoral Science Foundation (2018M642662)
- Government of Jiangsu Province
- Natural Science Foundation of Jiangsu Province (SBK2020042706)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
- Keywords
- SARS-CoV-2, membrane proteins, interferon evasion, type I interferon, interferon lambda, RIG-I, MDA5, MAVS, TBK1, IRF3, vesicular stomatitis virus, poly(I:C), viral replication
- MeSH terms
- DEAD Box Protein 58, Interferon-Induced Helicase, IFIH1, COVID-19, SARS-CoV-2, Coronavirus M Proteins, Interferon Lambda, Animals, Chlorocebus aethiops, HeLa Cells, Humans, Interferon Type I, Interferons, Receptors, Immunologic, Vero Cells, Viral Matrix Proteins, Signal Transduction, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review